GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

GSK (GSK) stock is in focus as the company is nearing a $1B deal to acquire IDRx, a private biotech focused on a rare ...

--Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial Times ...

GSK (GSK) is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal ...

Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy ...

Outside the FTSE 350, a big downwards mover is RBG Holdings PLC (AIM:RBGP), the holding company for law firms Rosenblatt and Memery Crystal.

GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.

In a report released today, William Katz from TD Cowen maintained a Buy rating on Blackstone Group (BX – Research Report), with a price target ...

The benchmark U.S. 10-year Treasury yield (US10Y) on Wednesday hit levels not seen since November 2023. Read more on the move ...

But we'll be back tomorrow with more updates on the war in Ukraine. Here are the key lines from today: Outgoing US defence secretary Lloyd Austin announced a $500m (£407m) aid package for Ukraine ...